Previous close | 40.37 |
Open | 40.13 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's range | 39.96 - 40.70 |
52-week range | 31.01 - 50.21 |
Volume | |
Avg. volume | 3,643,913 |
Market cap | 20.547B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.16 (2.88%) |
Ex-dividend date | 29 Feb 2024 |
1y target est | N/A |
Besides Wall Street's top -and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
ResMed (RMD) delivered earnings and revenue surprises of 10.94% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?